medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2022, Number Esp

Next >>

Rev Med UAS 2022; 12 (Esp)

Predominant chronic degenerative phenotypic features associated with Down syndrome: A narrative review

Esparza-Ocampo K, Chaidez-Fernández Y, Magaña-Ordorica D, Angulo-Rojo C, Guadrón-Llanos A, Castro-Apodaca F, Magaña-Gómez J

Language: Spanish
References: 61
Page: 3-22
PDF size: 447.54 Kb.


ABSTRACT

Down syndrome (DS) is the most common chromosomopathy, with a prevalence of 3.7 and 2.9 per 10,000 births in Mexico and Sinaloa, respectively. Although life expectancy has been increasing in this population, from 8 years five decades ago to 60 years today, it also leads to the appearance of chronic and degenerative conditions typical of aging, and apparently of greater risk in this population. Conditions such as intellectual disability, ophthalmic disorders, congenital cardiac malformations, gastrointestinal disorders, metabolic disorders such as overweight, obesity and diabetes, Alzheimer's disease, leukemia, thyroid disease, ischemic and cerebrovascular disease are frequent causes of morbidity and mortality. Therefore, knowledge of the clinical aspects of these patients will help to improve prevention and intervention programs, reduce complications and improve the care and quality of life of this population.


REFERENCES

  1. King E, Remington M, Berger H. Familyperspectives on gaps in health care for peoplewith Down syndrome. Am J Med GenetA. 2022;188(4):1160-9.

  2. de Graaf G, Buckley F, Skotko BG. Estimationof the number of people with Down syndromein the United States. Genet Med.2017;19(4):439-47.

  3. de Graaf G, Vis JC, Haveman M, van HoveG, de Graaf EAB, Tijssen JGP, et al. Assessmentof prevalence of persons with Downsyndrome: A theory-based demographic model.J Appl Res Intellect Disabil.2011;24(3):247-62.

  4. Sierra RM, Navarrete HE, Canun SS, ReyesPAE, Valdes HJ. [Prevalence of Down syndromeusing certificates of live births and fetaldeaths in Mexico 2008-2011]. Bol MedHosp Infant Mex. 2014;71(5):292-7.

  5. Weijerman ME, van Furth AM, Vonk NoordegraafA, van Wouwe JP, Broers CJ, GemkeRJ. Prevalence, neonatal characteristics,and first-year mortality of Down syndrome: anational study. J Pediatr. 2008;152(1):15-9.

  6. Calderón-Alvarado AB, del Sagrario Rojas-Villegas M, Dehesa-López E. Prevalencia demalformaciones congénitas detectadas alnacimiento en un hospital de segundo nivelen Sinaloa. Acta Pediatr Méx.2018;38(6):363-70.

  7. Iulita MF, Garzón CD, Klitgaard CM, ValleTN, Plana-Ripoll O, Rasmussen SA, et al.Association of Alzheimer disease with lifeexpectancy in people with Down syndrome.JAMA Netw Open. 2022;5(5):e2212910.

  8. Kennedy N, Kennedy J, Kerr M, Dredge S,Brophy S. Health checks for adults with intellectualdisability and association with survivalrates: a linked electronic records matchedcohort study in Wales, UK. BMJ Open.2022;12(4):e049441.

  9. Muñoz-Ortiz J, Charry-Sánchez JD, Bechara-Arango I, Blanco-Becerra M, Talero-Gutiérrez C, Gomez-Suarez M, et al. Prevalenceof ophthalmological manifestations inpediatric and adolescent populations withDown syndrome: a systematic review of theliterature. Syst Rev. 2022;11(1):75.

  10. Schworer EK, Ahmed A, Hogenkamp L,Moore S, Esbensen AJ. Associations amongco-occurring medical conditions and cognition,language, and behavior in Down syndrome.Res Dev Disabil. 2022;126:104236.

  11. Antonarakis SE. Down syndrome and thecomplexity of genome dosage imbalance.Nat Rev Genet. 2017;18(3):147-63.

  12. Antonarakis SE, Lyle R, Dermitzakis ET,Reymond A, Deutsch S. Chromosome 21and down syndrome: from genomics topathophysiology. Nat Rev Genet.2004;5(10):725-38.

  13. Antonaros F, Zenatelli R, Guerri G, BertelliM, Locatelli C, Vione B, et al. The transcriptomeprofile of human trisomy 21 blood cells.Hum Genomics. 2021;15(1):25.

  14. Montoya JC, Soto J, Satizábal JM, SánchezA, García F. Genomic study of the critical regionof chromosome 21 associated to Downsyndrome. Colomb Med. 2011;42(1):26-38.

  15. Pelleri MC, Cicchini E, Petersen MB, TranebjaergL, Mattina T, Magini P, et al. Partialtrisomy 21 map: Ten cases further supportingthe highly restricted Down syndrome criticalregion (HR-DSCR) on human chromosome21. Mol Genet Genomic Med.2019;7(8):e797.

  16. Korbel JO, Tirosh-Wagner T, Urban AE,Chen X-N, Kasowski M, Dai L, et al. The geneticarchitecture of Down syndrome phenotypesrevealed by high-resolution analysis ofhuman segmental trisomies. Proc Natl AcadSci U S A. 2009;106(29):12031-6.

  17. Lana-Elola E, Watson-Scales SD, FisherEM, Tybulewicz VL. Down syndrome: searchingfor the genetic culprits. Dis ModelMech. 2011;4(5):586-95.

  18. Patterson D. Molecular genetic analysis ofDown syndrome. Hum Genet.2009;126(1):195-214.

  19. Jyothy A, Rao GN, Kumar KS, Rao VB, DeviBU, Reddy PP. Translocation Down syndrome.Indian J Med Sci. 2002;56(3):122-6.

  20. Antonarakis SE, Skotko BG, Rafii MS,Strydom A, Pape SE, Bianchi DW, et al.Down syndrome. Nat Rev Dis Primers.2020;6(1):9-.

  21. Biselli JM, Zampieri BL, Biselli-Chicote PM,de Souza JES, Bürger MC, da Silva WA, Jr.,et al. Differential microRNA expression profilein blood of children with Down syndromesuggests a role in immunological dysfunction.Hum Cell. 2022;35(2):639-48.

  22. Amr NH. Thyroid disorders in subjects withDown syndrome: An update. Acta Biomed.2018;89(1):132-9.

  23. Fernández-Alcaraz C, Carvajal F. Neuropsychologicalprofile of adults with Downsyndrome and moderate intellectual disability.Res Dev Disabil. 2020;107:103781.

  24. Grieco J, Pulsifer M, Seligsohn K, Skotko B,Schwartz A. Down syndrome: Cognitive andbehavioral functioning across the lifespan.Am J Med Genet C Semin Med Genet.2015;169(2):135-49.

  25. Asim A, Agarwal S. Congenital heart defectsamong Down's syndrome cases: an updatedreview from basic research to an emergingdiagnostics technology and genetic counselling.J Genet. 2021;100.

  26. Taura MG, Alshahrani AM, Alqahtani DO.Prevalence of congenital heart diseaseamong patients with down syndrome inSouthwestern Saudi Arabia. Ann Afr Med.2021;20(4):265-9.

  27. Bermudez B, de Oliveira CM, de Lima CatMN, Magdalena NIR, Celli A. Gastrointestinaldisorders in Down syndrome. Am J MedGenet A. 2019;179(8):1426-31.

  28. Saberi RA, Gilna GP, Slavin BV, Huerta CT,Ramsey WA, O'Neil CF, Jr., et al. Hirschsprungdisease in Down syndrome: An opportunityfor improvement. J Pediatr Surg.2022;57(6):1040-4.

  29. Kaczorowska N, Kaczorowski K, LaskowskaJ, Mikulewicz M. Down syndrome as a causeof abnormalities in the craniofacial region: Asystematic literature review. Adv Clin ExpMed. 2019;28(11):1587-92.

  30. Mazurek D, Wyka J. Down syndrome-geneticand nutritional aspects of accompanyingdisorders. Rocz Panstw Zakl Hig.2015;66(3).

  31. Gensous N, Bacalini MG, Franceschi C, GaragnaniP. Down syndrome, acceleratedaging and immunosenescence. Semin Immunopathol.2020;42(5):635-45.

  32. Gensous N, Franceschi C, Salvioli S, GaragnaniP, Bacalini MG. Down syndrome,ageing and epigenetics. Subcell Biochem.2019;91:161-93.

  33. Hill DL, Parks EP, Zemel BS, Shults J, StallingsVA, Stettler N. Resting energy expenditureand adiposity accretion among childrenwith Down syndrome: a 3-year prospectivestudy. Eur J Clin Nutr.2013;67(10):1087-91.

  34. Saghazadeh A, Mahmoudi M, DehghaniAshkezari A, Oliaie Rezaie N, Rezaei N.Systematic review and meta-analysis showsa specific micronutrient profile in people withDown Syndrome: Lower blood calcium, seleniumand zinc, higher red blood cell copperand zinc, and higher salivary calcium and sodium.PLoS One. 2017;12(4):e0175437.

  35. Startin CM, Ashton NJ, Hamburg S, HithersayR, Wiseman FK, Mok KY, et al. Plasmabiomarkers for amyloid, tau, and cytokines inDown syndrome and sporadic Alzheimer'sdisease. Alzheimers Res Ther.2019;11(1):26.

  36. Guaraldi F, Rossetto Giaccherino R, LanfrancoF, Motta G, Gori D, Arvat E, et al. Endocrineautoimmunity in Down's syndrome.Front Horm Res. 2017;48:133-46.

  37. Bertapelli F, Pitetti K, Agiovlasitis S, Guerra-Junior G. Overweight and obesity in childrenand adolescents with Down syndrome-prevalence,determinants, consequences, andinterventions: A literature review. Res DevDisabil. 2016;57:181-92.

  38. Real de Asua D, Parra P, Costa R, MoldenhauerF, Suarez C. Evaluation of the impactof abdominal obesity on glucose and lipidmetabolism disorders in adults with Downsyndrome. Res Dev Disabil.2014;35(11):2942-9.

  39. Roccatello G, Cocchi G, DimastromatteoRT, Cavallo A, Biserni GB, Selicati M, et al.Eating and lifestyle habits in youth withDown syndrome attending a care program:An exploratory lesson for future improvements.Front Nutr. 2021;8:641112.

  40. Flores Arizmendi KA, García De La PuenteS, González Navarro M, Bonillo Suarez L,De León Becerra AG, Valderrama HernándezA, et al. Growth charts for Mexican childrenwith Down syndrome. Am J Med GenetA. 2022;188(4):1170-83.

  41. Pessoa DMF, da Paz ON, de Santana DG,de Fátima TFV, de Noronha RM, Calliari LE.Characteristics of type 1 diabetes mellitus inchildren and adolescents with Down's syndromein an admixed population. Arch EndocrinolMetab. 2021;65(5):562-9.

  42. Fortea J, Zaman SH, Hartley S, Rafii MS,Head E, Carmona-Iragui M. Alzheimer's diseaseassociated with Down syndrome: agenetic form of dementia. Lancet Neurol.2021;20(11):930-42.

  43. Hartley D, Blumenthal T, Carrillo M, DiPaoloG, Esralew L, Gardiner K, et al. Down syndromeand Alzheimer's disease: Commonpathways, common goals. Alzheimers Dement.2015;11(6):700-9.

  44. Kłosowska A, Ćwiklińska A, Kuchta A, BerlińskaA, Jankowski M, Wierzba J. Downsyndrome, increased risk of dementia and lipiddisturbances. Dev Period Med.2017;21(1):69-73.

  45. Agiovlasitis S, McCubbin JA, Yun J, PavolMJ, Widrick JJ. Economy and preferredspeed of walking in adults with and withoutDown syndrome. Adapt Phys Activ Q.2009;26(2):118-30.

  46. Pitetti K, Baynard T, Agiovlasitis S. Childrenand adolescents with Down syndrome, physicalfitness and physical activity. J SportHealth Sci. 2013;2(1):47-57.

  47. Buitenkamp TD, Izraeli S, Zimmermann M,Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemiain children with Down syndrome: a retrospectiveanalysis from the Ponte di Legnostudy group. Blood. 2014;123(1):70-7.

  48. Hertzberg L, Vendramini E, Ganmore I, CazzanigaG, Schmitz M, Chalker J, et al. Downsyndrome acute lymphoblastic leukemia, ahighly heterogeneous disease in which aberrantexpression of CRLF2 is associated withmutated JAK2: a report from the InternationalBFM Study Group. Blood.2010;115(5):1006-17.

  49. Mateos MK, Barbaric D, Byatt S-A, Sutton R,Marshall GM. Down syndrome and leukemia:insights into leukemogenesis andtranslational targets. Transl Pediatr.2015;4(2):76.

  50. Triarico S, Trombatore G, Capozza MA, RomanoA, Mastrangelo S, Attinà G, et al. Hematologicaldisorders in children with Downsyndrome. Expert Rev Hematol.2022;15(2):127-35.

  51. Hawli Y, Nasrallah M, Fuleihan GE-H. Endocrineand musculoskeletal abnormalities inpatients with Down syndrome. Nat Rev Endocrinol.2009;5(6):327.

  52. Johnson MB, De Franco E, Greeley SAW,Letourneau LR, Gillespie KM, Wakeling MN,et al. Trisomy 21 is a cause of permanentneonatal diabetes that is autoimmune butnot HLA associated. Diabetes.2019;68(7):1528-35.

  53. Tenneti N, Dayal D, Sharda S, Panigrahi I,Didi M, Attri SV, et al. Concentrations of leptin,adiponectin and other metabolic parametersin non-obese children with Down syndrome.J Pediatr Endocrinol Metab.2017;30(8):831-7.

  54. Corsi MM, Dogliotti G, Pedroni F, Galliera E,Malavazos AE, Villa R, et al. Adipocytokinesin Down's syndrome, an atheroma-free model:Role of adiponectin. Arch Gerontol Geriatr.2009;48(1):106-9.

  55. Adelekan T, Magge S, Shults J, Stallings V,Stettler N. Lipid profiles of children withDown syndrome compared with their siblings.Pediatrics. 2012;129(6):e1382-7.

  56. Buonuomo PS, Bartuli A, Mastrogiorgio G,Vittucci A, Di Camillo C, Bianchi S, et al. Lipidprofiles in a large cohort of Italian childrenwith Down syndrome. Eur J Med Genet.2016;59(8):392-5.

  57. Garcia-de la Puente S, Flores-Arizmendi KA,Delgado-Montemayor MJ, Vargas-RobledoTT. Lipid profile of Mexican children withDown syndrome. BMC Pediatrics.2021;21(1):77.

  58. Pueschel S, Craig W, Haddow J. Lipids andlipoproteins in persons with Down's syndrome.J Intellect Disabil Res.1992;36(4):365-9.

  59. Zamorano A, Guzmán M, Aspillaga M, AvendañoA, Gatica M. Concentrations of serumlipids in children with Down's syndrome.Arch Biol Med Exp. 1991;24(1):49-55.

  60. de la Piedra MJ, Alberti G, Cerda J, CárdenasA, Paul MA, Lizama M. Alta frecuenciade dislipidemias en niños y adolescentescon Síndrome de Down. Rev Chil Pediatr.2017;88:595-601.

  61. Chaney RH. Neurogenic atherosclerosis inmentally retarded persons. J Intellect DisabilRes. 1987;31(3):235-40.




2020     |     www.medigraphic.com